Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 45

1.

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.

Lilly MB, Ottmann OG, Shah NP, Larson RA, Reiffers JJ, Ehninger G, Müller MC, Charbonnier A, Bullorsky E, Dombret H, Brigid Bradley-Garelik M, Zhu C, Martinelli G.

Am J Hematol. 2010 Mar;85(3):164-70. doi: 10.1002/ajh.21615.

PMID:
20131302
[PubMed - indexed for MEDLINE]
2.

New approved dasatinib regimen available for clinical use.

Snyder DS.

Expert Rev Anticancer Ther. 2009 Mar;9(3):285-92. doi: 10.1586/14737140.9.3.285. Review.

PMID:
19275507
[PubMed - indexed for MEDLINE]
3.

Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia.

Wong SF.

J Oncol Pharm Pract. 2009 Mar;15(1):17-27. doi: 10.1177/1078155208094455. Epub 2008 Aug 27. Review.

PMID:
18753186
[PubMed - indexed for MEDLINE]
4.

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.

Tyler T.

Ann Pharmacother. 2009 May;43(5):920-7. doi: 10.1345/aph.1L570. Epub 2009 Mar 31. Review.

PMID:
19336654
[PubMed - indexed for MEDLINE]
5.
6.

Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Keam SJ.

BioDrugs. 2008;22(1):59-69. Review.

PMID:
18215092
[PubMed - indexed for MEDLINE]
7.

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

McCormack PL, Keam SJ.

Drugs. 2011 Sep 10;71(13):1771-95. doi: 10.2165/11207580-000000000-00000. Review.

PMID:
21902298
[PubMed - indexed for MEDLINE]
8.

New dosing schedules of dasatinib for CML and adverse event management.

Wong SF.

J Hematol Oncol. 2009 Feb 23;2:10. doi: 10.1186/1756-8722-2-10. Review.

PMID:
19236716
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.

Abbott BL.

Clin Ther. 2012 Feb;34(2):272-81. doi: 10.1016/j.clinthera.2012.01.009. Epub 2012 Jan 27. Review.

PMID:
22285209
[PubMed - indexed for MEDLINE]
10.

Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.

Hochhaus A.

Expert Opin Pharmacother. 2007 Dec;8(18):3257-64. Review.

PMID:
18035968
[PubMed - indexed for MEDLINE]
11.

Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.

Breccia M, Alimena G.

Expert Opin Drug Saf. 2010 Sep;9(5):713-21. doi: 10.1517/14740331003742935. Review.

PMID:
20722490
[PubMed - indexed for MEDLINE]
12.

Dasatinib: is it all in the dose?

Condorelli F, Genazzani AA.

BioDrugs. 2010 Jun;24(3):157-63. doi: 10.2165/11535870-000000000-00000. Review.

PMID:
20222756
[PubMed - indexed for MEDLINE]
13.

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

Erba HP, Pham DC, Zaiden R, Vu H, Tai S.

Clin Adv Hematol Oncol. 2011 Oct;9(10):734-45. Review.

PMID:
22252576
[PubMed - indexed for MEDLINE]
14.

Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.

Santos FP, Cortes J.

Expert Opin Pharmacother. 2012 Nov;13(16):2381-95. doi: 10.1517/14656566.2012.725722. Epub 2012 Sep 20. Review.

PMID:
22992064
[PubMed - indexed for MEDLINE]
15.

Dasatinib: an anti-tumour agent via Src inhibition.

Gnoni A, Marech I, Silvestris N, Vacca A, Lorusso V.

Curr Drug Targets. 2011 Apr;12(4):563-78. Review.

PMID:
21226671
[PubMed - indexed for MEDLINE]
16.

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.

Wei G, Rafiyath S, Liu D.

J Hematol Oncol. 2010 Nov 26;3:47. doi: 10.1186/1756-8722-3-47. Review.

PMID:
21108851
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.

Breccia M, Alimena G.

BioDrugs. 2011 Jun 1;25(3):147-57. doi: 10.2165/11591840-000000000-00000. Review.

PMID:
21528941
[PubMed - indexed for MEDLINE]
18.

Dasatinib.

Lindauer M, Hochhaus A.

Recent Results Cancer Res. 2010;184:83-102. doi: 10.1007/978-3-642-01222-8_7. Review.

PMID:
20072833
[PubMed - indexed for MEDLINE]
19.

Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.

Piccaluga PP, Paolini S, Martinelli G.

Cancer. 2007 Sep 15;110(6):1178-86. Review.

PMID:
17701954
[PubMed - indexed for MEDLINE]
Free Article
20.

Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Stock W.

Leuk Lymphoma. 2010 Feb;51(2):188-98. doi: 10.3109/10428190903452834. Review.

PMID:
20001232
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk